Kytopen is a spin out of MIT developing proprietary platforms for non-viral delivery of payloads for ex vivo cell therapy discovery and manufacturing. The scalable solution leverages electro-mechanical energy to make transfection easier, faster, and more cost-effective than the state-of-the art solutions. Kytopen has integrated their platforms with automated liquid handling systems for processing small volumes and also has developed a large volume platform for therapeutic manufacturing applications. This non-viral solution will accelerate the time-to-market of next-generation cell and gene therapies by enabling discovery of therapeutic targets and direct transfer to a scaled manufacturing solution, reducing cell therapy manufacturing complexity and cost. Kytopen recently closed a $32M Series A financing and is actively exploring strategic partnership opportunities. In this talk we intend to provide a general overview of the non-viral transfection platforms we are developing for ex vivo cell therapy discovery and manufacturing for clinically relevant cell types such as T cells, NK cells, and hematapoietic stem cells.